Barbieri M, Bonafe M, Rizzo MR, Ragno E, Olivieri F, Marchegiani F, Franceschi C, Paolisso G
full Phase 3 data are required before regulatory submission or NHS use
The CREDENCE clinical trial evaluated the effects of canagliflozin 100 mg daily versus placebo in 4401 patients with T2DM and chronic kidney disease (CKD)
For patients, prescribers, and compounding pharmacies watching the GLP-1 supply-and-regulation churn, monthly dosing is a simple promise: fewer injections, fewer opportunities to miss doses, fewer shipments, and a different adherence curve
Consequently, oxidative stress has the potential to disrupt the equilibrium within melanocytes, causing significant metabolic disorders, including cells viability decrease or even their malignant metamorphosis 56